Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Pancreatic Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
25 drugs · 152 active trials
4 drugs · 116 active trials
8 drugs · 222 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 15 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Capivasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| CAPOX Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 15, 2023 |
| Carboplatin/Pemetrexed Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Aug 11, 2022 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Daratumumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 31, 2024 |
| Datopotamab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Enfortumab Vedotin | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 30, 2023 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Etoposide | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 6, 2015 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Galeterone | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Dec 12, 2019 |
| Histamine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2024 |
| Hyperthermic Intraperitoneal Chemotherapy | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 15, 2024 |
| Immunotherapy | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 26, 2025 |
| Ipatasertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Lomustine | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 4, 2019 |
| Lutetium (177lu) Oxodotreotide | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Feb 16, 2023 |
| Pimicotinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 17, 2023 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Tivozanib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 7, 2021 |
| Trastuzumab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Zanidatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 14, 2025 |
| Zoledronic Acid | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 16, 2016 |
| Everolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2004-12 |
| Sorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 2007-09 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | Aug 11, 2017 |
| Filgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 1997-03 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2007-03 |
| Sirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2005-01 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2003-12 |
| MVT Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2016-01 |
| Vorinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2009-05 |
| Abemaciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Jun 29, 2016 |
| Azacitidine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2010-07 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Mar 29, 2012 |
| Lenalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2005-04 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2004-03 |
| Sonidegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Dec 27, 2011 |
| Tipifarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2000-05 |
| Conatumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-06 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2002-08 |
| Rucaparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2014-04 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-07 |
| Vatalanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-10 |
| Vemurafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Apr 1, 2020 |
| Acalabrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2015-05 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-09 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-08 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-08 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.